CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 39,000 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $18.33, for a total transaction of $714,870.00. Following the completion of the sale, the chief executive officer directly owned 816,317 shares of the company’s stock, valued at $14,963,090.61. The trade was a 4.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The shares were sold at an average price of $18.00, for a total transaction of $108,540.00.
• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $20.10, for a total transaction of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.40, for a total transaction of $717,600.00.

CeriBell Stock Down 0.6%

Shares of NASDAQ:CBLL opened at $18.38 on Thursday. The company has a 50 day moving average price of $18.98 and a two-hundred day moving average price of $19.67. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $24.33. The company has a market capitalization of $697.39 million, a PE ratio of -11.28 and a beta of 0.84.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The company had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. Analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CBLL. Bank of New York Mellon Corp raised its stake in shares of CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after purchasing an additional 1,162,200 shares in the last quarter. KCM Capital Inc bought a new position in shares of CeriBell in the fourth quarter valued at $21,930,000. Royce & Associates LP bought a new position in shares of CeriBell in the fourth quarter valued at $11,695,000. Adage Capital Partners GP L.L.C. acquired a new position in CeriBell during the fourth quarter worth $10,965,000. Finally, CenterBook Partners LP raised its position in CeriBell by 448.0% during the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock worth $5,476,000 after acquiring an additional 389,584 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.